JP6883988B2 - ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 - Google Patents

ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 Download PDF

Info

Publication number: JP6883988B2
Authority: JP; Japan
Prior art keywords: alkyl; aliphatic; isomer; aryl; independently
Prior art date: 2013-12-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2016541280A

Other languages

English (en)

Japanese (ja)

Other versions

JP2017500334A (ja

JP2017500334A5 (2

Inventor

ブリューメコネン，

ジョンエー．ブテーラ，

ジアンシンフアン，

Original Assignee

エージンバイオ，インコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-20

Filing date

2014-12-19

Publication date

2021-06-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53403769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6883988(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-12-19 Application filed by エージンバイオ，インコーポレイテッド, エージンバイオ，インコーポレイテッド filed Critical エージンバイオ，インコーポレイテッド

2017-01-05 Publication of JP2017500334A publication Critical patent/JP2017500334A/ja

2018-02-01 Publication of JP2017500334A5 publication Critical patent/JP2017500334A5/ja

2021-06-09 Application granted granted Critical

2021-06-09 Publication of JP6883988B2 publication Critical patent/JP6883988B2/ja

Status Active legal-status Critical Current

2034-12-19 Anticipated expiration legal-status Critical

Links

VDGKBDLBPWKJAK-UHFFFAOYSA-N CC(C)c1nc(-c(nc2)c3[n]2-c(ccc(F)c2)c2-[n]2nnc(C)c2C3)n[o]1 Chemical compound CC(C)c1nc(-c(nc2)c3[n]2-c(ccc(F)c2)c2-[n]2nnc(C)c2C3)n[o]1 VDGKBDLBPWKJAK-UHFFFAOYSA-N 0.000 description 1
0 CC(C=C1)(C=CC2=C1c1nnc(*)[n]1C(*)(*)c1c(*)nc(*)[n]21)N=* Chemical compound CC(C=C1)(C=CC2=C1c1nnc(*)[n]1C(*)(*)c1c(*)nc(*)[n]21)N=* 0.000 description 1
QUQGSDPJGVVZLK-UHFFFAOYSA-N CCOC(c(nc1)c2[n]1-c(ccc(OC)c1)c1-[n]1nnc(CN3CCOCC3)c1C2)=O Chemical compound CCOC(c(nc1)c2[n]1-c(ccc(OC)c1)c1-[n]1nnc(CN3CCOCC3)c1C2)=O QUQGSDPJGVVZLK-UHFFFAOYSA-N 0.000 description 1
NCAKYTYHUOGYAQ-UHFFFAOYSA-N CCc(nc1)c2[n]1-c(cccc1)c1-[n]1nnc(C)c1C2 Chemical compound CCc(nc1)c2[n]1-c(cccc1)c1-[n]1nnc(C)c1C2 NCAKYTYHUOGYAQ-UHFFFAOYSA-N 0.000 description 1
QGLIGNDLHDFWRD-UHFFFAOYSA-N Cc1c(Cc([n](cn2)-c(cc3)c-4cc3F)c2S(c2ccc(C)cc2)(=O)=O)[n]-4nn1 Chemical compound Cc1c(Cc([n](cn2)-c(cc3)c-4cc3F)c2S(c2ccc(C)cc2)(=O)=O)[n]-4nn1 QGLIGNDLHDFWRD-UHFFFAOYSA-N 0.000 description 1
TXTFDYFURDPKJN-UHFFFAOYSA-N Cc1c(Cc2c(-c3ccccc3)nc[n]2-c(cc2)c-3cc2F)[n]-3nn1 Chemical compound Cc1c(Cc2c(-c3ccccc3)nc[n]2-c(cc2)c-3cc2F)[n]-3nn1 TXTFDYFURDPKJN-UHFFFAOYSA-N 0.000 description 1
JBUHHHOXISISNK-UHFFFAOYSA-N Cc1c(Cc2c(-c3ccnc(C)c3)nc[n]2-c(cc2)c-3cc2F)[n]-3nn1 Chemical compound Cc1c(Cc2c(-c3ccnc(C)c3)nc[n]2-c(cc2)c-3cc2F)[n]-3nn1 JBUHHHOXISISNK-UHFFFAOYSA-N 0.000 description 1
ZYYHUPIQNILVCJ-UHFFFAOYSA-N Cc1c(Cc2c(-c3n[o]c(C)n3)nc[n]2-c(cc2)c-3cc2F)[n]-3nn1 Chemical compound Cc1c(Cc2c(-c3n[o]c(C)n3)nc[n]2-c(cc2)c-3cc2F)[n]-3nn1 ZYYHUPIQNILVCJ-UHFFFAOYSA-N 0.000 description 1
YLGQFTNYRUWYRU-UHFFFAOYSA-N Cc1nc(-c(nc2)c(C[n]3c(-c4c5)nnc3COc(cc3)ccc3F)[n]2-c4ccc5OC)n[o]1 Chemical compound Cc1nc(-c(nc2)c(C[n]3c(-c4c5)nnc3COc(cc3)ccc3F)[n]2-c4ccc5OC)n[o]1 YLGQFTNYRUWYRU-UHFFFAOYSA-N 0.000 description 1
XBYCVYXKCQVAER-UHFFFAOYSA-N Cc1nc(-c(nc2)c3[n]2-c(ccc(OC)c2)c2-[n]2nnc(COc4cccc(F)c4)c2C3)n[o]1 Chemical compound Cc1nc(-c(nc2)c3[n]2-c(ccc(OC)c2)c2-[n]2nnc(COc4cccc(F)c4)c2C3)n[o]1 XBYCVYXKCQVAER-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Physical Education & Sports Medicine (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Quinoline Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

JP2016541280A 2013-12-20 2014-12-19 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 Active JP6883988B2 (ja)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201361919390P	2013-12-20	2013-12-20
US201361919394P	2013-12-20	2013-12-20
US61/919,390		2013-12-20
US61/919,394		2013-12-20
US201462075743P	2014-11-05	2014-11-05
US62/075,743		2014-11-05
PCT/US2014/071644 WO2015095783A1 (en)	2013-12-20	2014-12-19	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2019193538A Division JP2020011998A (ja)	2013-12-20	2019-10-24	ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP2021031721A Division JP2021080287A (ja)	2013-12-20	2021-03-01	ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法

Publications (3)

Publication Number	Publication Date
JP2017500334A JP2017500334A (ja)	2017-01-05
JP2017500334A5 JP2017500334A5 (2)	2018-02-01
JP6883988B2 true JP6883988B2 (ja)	2021-06-09

Family

ID=53403769

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
JP2016541280A Active JP6883988B2 (ja)	2013-12-20	2014-12-19	ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP2019193538A Pending JP2020011998A (ja)	2013-12-20	2019-10-24	ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP2021031721A Withdrawn JP2021080287A (ja)	2013-12-20	2021-03-01	ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
JP2019193538A Pending JP2020011998A (ja)	2013-12-20	2019-10-24	ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP2021031721A Withdrawn JP2021080287A (ja)	2013-12-20	2021-03-01	ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法

Country Status (11)

Country	Link
US (2)	US10329301B2 (2)
EP (2)	EP3083569B1 (2)
JP (3)	JP6883988B2 (2)
CN (2)	CN106068256B (2)
AU (1)	AU2014368961B2 (2)
CA (2)	CA3123897C (2)
IL (1)	IL246261B (2)
MX (2)	MX391314B (2)
NZ (2)	NZ760341A (2)
WO (1)	WO2015095783A1 (2)
ZA (1)	ZA201605027B (2)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3034079B1 (en)	2010-11-15	2018-01-10	Agenebio, Inc.	Pyridazine derivatives, compositions and methods for treating cognitive impairment
NZ760341A (en)	2013-12-20	2021-12-24	Agenebio Inc	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX392119B (es)	2015-06-19	2025-03-11	Agenebio Inc	Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo
US10449181B2 (en)	2016-08-25	2019-10-22	Sarah E. Labance	Treatment of autism and autism spectrum disorders (ASD)
US11505555B2 (en)	2016-12-19	2022-11-22	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) *	2016-12-19	2018-06-21	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN112601749B (zh) *	2018-06-19	2024-03-26	艾吉因生物股份有限公司	用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
CA3129749A1 (en) *	2019-02-13	2020-08-20	Centre For Addiction And Mental Health	Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors
AU2020286381C1 (en)	2019-06-04	2025-07-10	Hager Biosciences, Llc	Imidazolo derivatives, compositions and methods as orexin antagonists
JP7737721B2 (ja) *	2019-12-19	2025-09-11	エージンバイオ，インコーポレイテッド	認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
TWI901650B (zh)	2020-03-26	2025-10-21	匈牙利商羅特格登公司	啶及吡啶并〔３，４－ｃ〕嗒衍生物
WO2022011314A1 (en) *	2020-07-10	2022-01-13	Agenebio, Inc.	POLYMORPHS OF A GABAA α5 AGONIST AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT
CN116075302A (zh) *	2020-07-10	2023-05-05	艾吉因生物股份有限公司	GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法
CN113284553B (zh) *	2021-05-28	2023-01-10	南昌大学	一种用于治疗药物成瘾的药物靶点结合能力测试方法
HU231691B1 (hu)	2021-09-29	2025-10-28	Richter Gedeon Nyrt	GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CN120584115A (zh)	2022-08-19	2025-09-02	艾吉因生物股份有限公司	苯并氮杂䓬衍生物、组合物和用于治疗认知损害的方法
US20250375429A1 (en)	2024-05-29	2025-12-11	Smarter Not Harder, Inc.	Obligate pairing of orthosteric and non-orthosteric gaba ligands in pharmaceutical formulations

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3391142A (en)	1966-02-09	1968-07-02	Lilly Co Eli	Adamantyl secondary amines
US3539573A (en)	1967-03-22	1970-11-10	Jean Schmutz	11-basic substituted dibenzodiazepines and dibenzothiazepines
ES413944A1 (es)	1972-04-20	1976-06-01	Merz & Co	Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
NL7605526A (nl)	1976-05-24	1977-11-28	Akzo Nv	Nieuwe tetracyclische derivaten.
JPS54130587A (en)	1978-03-30	1979-10-09	Otsuka Pharmaceut Co Ltd	Carbostyryl derivative
DE2856393C2 (de)	1978-12-27	1983-04-28	Merz + Co GmbH & Co, 6000 Frankfurt	Arzneimittel zur Behandlung von Morbus Parkinson
US4804663A (en)	1985-03-27	1989-02-14	Janssen Pharmaceutica N.V.	3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en)	1985-04-10	1993-09-08	Lundbeck & Co As H	Indole derivatives
GB8607684D0 (en)	1986-03-27	1986-04-30	Ici America Inc	Thiazepine compounds
US4816456A (en)	1986-10-01	1989-03-28	Summers William K	Administration of monoamine acridines in cholinergic neuronal deficit states
NL195004C (nl)	1987-03-04	2003-11-04	Novartis Ag	Fenylcarbamaat bevattend farmaceutisch preparaat.
FI95572C (fi)	1987-06-22	1996-02-26	Eisai Co Ltd	Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4831031A (en)	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en)	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
CA2000786C (en)	1988-11-07	1999-01-26	Janssen Pharmaceutica, Naamloze Vennootschap	3-piperidinyl-1,2-benzisoxazoles
US5043345A (en)	1989-02-22	1991-08-27	Novo Nordisk A/S	Piperidine compounds and their preparation and use
ES2059602T3 (es)	1989-04-14	1994-11-16	Merz & Co Gmbh & Co	Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.
DE69021645T2 (de)	1989-05-19	1996-02-22	Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J.	N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
US5229382A (en)	1990-04-25	1993-07-20	Lilly Industries Limited	2-methyl-thieno-benzodiazepine
JP2807577B2 (ja)	1990-06-15	1998-10-08	エーザイ株式会社	環状アミド誘導体
JP2800953B2 (ja)	1990-07-06	1998-09-21	住友製薬株式会社	新規なイミド誘導体
DE69131268T2 (de) *	1990-09-21	1999-12-30	Rohm And Haas Co., Philadelphia	Dihydropyridazinone und Pyridazinone als Fungizide
US5190951A (en)	1990-10-19	1993-03-02	Ss Pharmaceutical Co., Ltd.	Quinoline derivatives
EP0586551A1 (en) *	1991-05-24	1994-03-16	E.I. Du Pont De Nemours And Company	Arthropodicidal anilides
US5106856A (en)	1991-06-07	1992-04-21	Hoechst-Roussel Pharmaceuticals Inc.	[(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
TW201311B (2) *	1991-06-17	1993-03-01	Hoffmann La Roche
US5312925A (en)	1992-09-01	1994-05-17	Pfizer Inc.	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
HK1008417A1 (en)	1994-03-02	1999-05-07	Merck Sharp & Dohme B.V.	Sublingual or buccal pharmaceutical composition
US6479523B1 (en)	1997-08-26	2002-11-12	Emory University	Pharmacologic drug combination in vagal-induced asystole
WO1999025353A1 (en)	1997-11-13	1999-05-27	Merck Sharp & Dohme Limited	Therapeutic uses of triazolo-pyridazine derivatives
US6294583B1 (en)	1998-01-13	2001-09-25	Synchroneuron, Llc	Methods of treating tardive dyskinesia and other movement disorders
US6391922B1 (en)	1998-01-13	2002-05-21	Synchroneuron, Llc	Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
WO2000027849A2 (en)	1998-11-12	2000-05-18	Merck & Co., Inc.	Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
US6677330B1 (en)	1999-03-03	2004-01-13	Eisai Co., Ltd.	Fluorides of 4-substituted piperidine derivatives
GB9911804D0 (en)	1999-05-20	1999-07-21	Merck Sharp & Dohme	Therapeutic combination
GB9911803D0 (en)	1999-05-20	1999-07-21	Merck Sharp & Dohme	Therapeutic combination
GB9911802D0 (en)	1999-05-20	1999-07-21	Merck Sharp & Dohme	Therapeutic combination
GB9929569D0 (en)	1999-12-14	2000-02-09	Merck Sharp & Dohme	Therapeutic agents
GB0004297D0 (en)	2000-02-23	2000-04-12	Ucb Sa	2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US20020151591A1 (en)	2000-10-17	2002-10-17	Anabella Villalobos	Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
TWI239333B (en) *	2000-11-16	2005-09-11	Hoffmann La Roche	Benzodiazepine derivatives as GABA A receptor modulators
PA8535601A1 (es)	2000-12-21	2002-11-28	Pfizer	Derivados benzimidazol y piridilimidazol como ligandos para gabaa
CZ20032338A3 (cs)	2001-03-01	2004-08-18	Pfizeráproductsáinc	Použití inversních agonistů GABA A v kombinaci s parciálními agonisty receptoru nikotinuŹ estrogenemŹ selektivními modulátory estrogenu nebo vitaminem E při léčení kognitivních poruch
US6686352B2 (en)	2001-05-18	2004-02-03	Hoffmann-La Roche Inc.	Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
AU2002313737A1 (en)	2001-08-13	2003-04-01	University Of Kentucky Research Foundation	Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment
EP1471909A4 (en)	2002-01-16	2007-07-25	Endo Pharmaceuticals Inc	PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
GB0218876D0 (en)	2002-08-13	2002-09-25	Merck Sharp & Dohme	Therapeutic agents
US20060235021A1 (en)	2002-08-13	2006-10-19	Wesley Blackaby	Phenylpyridazine derivatives as ligands for gaba receptors
US7635709B2 (en)	2002-09-26	2009-12-22	The United States Of America As Represented By The Department Of Veterans Affairs	Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
TW200418446A (en)	2002-10-24	2004-10-01	Merz Pharma Gmbh & Co Kgaa	Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
NZ540288A (en)	2002-11-22	2009-06-26	Univ Johns Hopkins	Target for therapy of cognitive impairment
WO2005079779A1 (en)	2003-10-22	2005-09-01	Merz Pharma Gmbh & Co. Kgaa	THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES
WO2006034465A1 (en)	2004-09-23	2006-03-30	Merz Pharma Gmbh & Co. Kgaa	Memantine for the treatment of childhood behavioral disorders
RU2007112675A (ru)	2004-10-12	2008-11-20	Ф.Хоффманн-Ля Рош Аг (Ch)	ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-a]ТРИАЗОЛО[1,5-d]БЕНЗОДИАЗЕПИНА ДЛЯ ЛЕЧЕНИЯ КОГНИТИВНЫХ РАССТРОЙСТВ
AU2005299031B2 (en)	2004-10-20	2011-11-10	F. Hoffmann-La Roche Ag	Halogen substituted benzodiazepine derivatives
MX2007004639A (es) *	2004-10-20	2007-06-08	Hoffmann La Roche	Derivados de imidazo-benzodiazepina.
EP1828194B1 (en) *	2004-12-14	2008-05-28	F. Hoffmann-Roche AG	Tetracyclic imidazo-benzodiazepines as gaba receptors modulators
US20060205822A1 (en)	2004-12-22	2006-09-14	Forest Laboratories, Inc.	1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US7595395B2 (en)	2005-05-16	2009-09-29	Wisys Technology Foundation	Gabaergic agents to treat memory deficits
US8510055B2 (en)	2005-08-03	2013-08-13	The Johns Hopkins University	Methods for characterizing and treating cognitive impairment in aging and disease
EP2682481A3 (en)	2005-08-03	2014-09-17	The Johns-Hopkins University	Methods for characterizing and treating cognitive impairment in aging and disease
BRPI0617204A2 (pt) *	2005-10-11	2011-07-19	Hoffmann La Roche	derivados de imidazo benzodiazepina
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
US8486979B2 (en)	2006-12-12	2013-07-16	Abbvie Inc.	1,2,4 oxadiazole compounds and methods of use thereof
US7943619B2 (en)	2007-12-04	2011-05-17	Hoffmann-La Roche Inc.	Isoxazolo-pyridazine derivatives
CA2730148C (en)	2008-08-01	2018-04-03	Lixte Biotechnology, Inc.	Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
KR20110059652A (ko)	2008-09-24	2011-06-02	이 아이 듀폰 디 네모아 앤드 캄파니	살진균제 피리다진
KR20110066952A (ko)	2008-09-25	2011-06-17	비브 나노, 인코포레이티드	중합체 나노입자 및 활성 성분의 제형을 제조하는 방법
EP2419401A2 (en)	2009-04-17	2012-02-22	XenoPort, Inc.	GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS
JP2013516497A (ja)	2010-01-11	2013-05-13	ミスリィディオン，インク．	認知増強のための化合物と組成物、製造方法、および治療方法
MX341471B (es)	2010-11-05	2016-08-22	Hoffmann La Roche	Uso de compuestos farmaceuticos activos para el tratamiento de estados patologicos del sistema nervioso central.
US20130237530A1 (en)	2010-11-15	2013-09-12	Agenebio, Inc.	Benzodiazepine derivatives, compositions and methods for treating cognitive impairment
EP3034079B1 (en)	2010-11-15	2018-01-10	Agenebio, Inc.	Pyridazine derivatives, compositions and methods for treating cognitive impairment
JPWO2012161133A1 (ja)	2011-05-20	2014-07-31	日産化学工業株式会社	置換ピリダジン化合物及び農園芸用殺菌剤
US20150374705A1 (en)	2012-02-14	2015-12-31	Shanghai Institues for Biological Sciences	Substances for treatment or relief of pain
CA2884566A1 (en)	2012-09-10	2014-03-13	Matthew R. Lewin	Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
NZ760341A (en)	2013-12-20	2021-12-24	Agenebio Inc	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX392119B (es)	2015-06-19	2025-03-11	Agenebio Inc	Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo
US20180170941A1 (en)	2016-12-19	2018-06-21	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN108567787A (zh)	2017-03-10	2018-09-25	辛衍雪	一种治疗慢性阻塞性肺病的药物组合物
CN112601749B (zh)	2018-06-19	2024-03-26	艾吉因生物股份有限公司	用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法

2014
- 2014-12-19 NZ NZ760341A patent/NZ760341A/en unknown
- 2014-12-19 US US15/104,494 patent/US10329301B2/en active Active
- 2014-12-19 CN CN201480073611.7A patent/CN106068256B/zh active Active
- 2014-12-19 EP EP14870710.2A patent/EP3083569B1/en active Active
- 2014-12-19 JP JP2016541280A patent/JP6883988B2/ja active Active
- 2014-12-19 AU AU2014368961A patent/AU2014368961B2/en active Active
- 2014-12-19 CA CA3123897A patent/CA3123897C/en active Active
- 2014-12-19 NZ NZ722077A patent/NZ722077A/en unknown
- 2014-12-19 MX MX2019010577A patent/MX391314B/es unknown
- 2014-12-19 CN CN202010983158.0A patent/CN112409363B/zh active Active
- 2014-12-19 EP EP21213904.2A patent/EP4032889B1/en active Active
- 2014-12-19 WO PCT/US2014/071644 patent/WO2015095783A1/en not_active Ceased
- 2014-12-19 CA CA2934553A patent/CA2934553C/en active Active
- 2014-12-19 MX MX2016007808A patent/MX381561B/es unknown
2016
- 2016-06-16 IL IL246261A patent/IL246261B/en active IP Right Grant
- 2016-07-19 ZA ZA2016/05027A patent/ZA201605027B/en unknown
2019
- 2019-05-31 US US16/428,394 patent/US11142529B2/en active Active
- 2019-10-24 JP JP2019193538A patent/JP2020011998A/ja active Pending
2021
- 2021-03-01 JP JP2021031721A patent/JP2021080287A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
MX391314B (es)	2025-03-21
US11142529B2 (en)	2021-10-12
MX2019010577A (es)	2019-10-21
JP2021080287A (ja)	2021-05-27
JP2017500334A (ja)	2017-01-05
WO2015095783A1 (en)	2015-06-25
JP2020011998A (ja)	2020-01-23
AU2014368961A1 (en)	2016-08-04
MX2016007808A (es)	2016-09-07
BR112016014564A2 (pt)	2017-08-08
NZ722077A (en)	2021-12-24
CA3123897C (en)	2024-02-06
EP4032889A1 (en)	2022-07-27
CN106068256B (zh)	2020-10-23
EP4032889B1 (en)	2026-05-06
AU2014368961A2 (en)	2016-11-10
ZA201605027B (en)	2023-04-26
CN112409363A (zh)	2021-02-26
CA2934553C (en)	2023-10-31
US20170253603A2 (en)	2017-09-07
CN106068256A8 (zh)	2018-10-30
CA3123897A1 (en)	2015-06-25
US20170022208A1 (en)	2017-01-26
EP3083569B1 (en)	2022-01-26
CN112409363B (zh)	2023-11-14
IL246261B (en)	2021-03-25
CA2934553A1 (en)	2015-06-25
CN106068256A (zh)	2016-11-02
AU2014368961B2 (en)	2019-10-17
EP3083569A1 (en)	2016-10-26
EP3083569A4 (en)	2017-10-04
US10329301B2 (en)	2019-06-25
IL246261A0 (en)	2016-08-02
MX381561B (es)	2025-03-12
NZ760341A (en)	2021-12-24
US20190284196A1 (en)	2019-09-19

Legal Events

Date	Code	Title	Description
2016-10-13	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161013
2017-12-18	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171218
2017-12-18	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171218
2018-09-25	A977	Report on retrieval	Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180913
2018-11-05	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181105
2019-02-01	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190201
2019-06-24	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190624
2019-10-24	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191024
2019-10-24	C60	Trial request (containing other claim documents, opposition documents)	Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20191024
2019-11-12	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20191111
2019-11-12	C21	Notice of transfer of a case for reconsideration by examiners before appeal proceedings	Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20191112
2019-12-23	A912	Re-examination (zenchi) completed and case transferred to appeal board	Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20191220
2019-12-24	C211	Notice of termination of reconsideration by examiners before appeal proceedings	Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20191224
2020-06-30	C22	Notice of designation (change) of administrative judge	Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200630
2020-08-31	C13	Notice of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20200831
2020-10-06	C22	Notice of designation (change) of administrative judge	Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20201006
2020-11-26	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201126
2020-12-21	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201221
2021-03-01	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210301
2021-03-22	C23	Notice of termination of proceedings	Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20210322
2021-04-15	C03	Trial/appeal decision taken	Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20210415
2021-04-15	C30A	Notification sent	Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20210415
2021-05-13	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210511
2021-05-13	R150	Certificate of patent or registration of utility model	Ref document number: 6883988 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2022-06-21	R157	Certificate of patent or utility model (correction)	Free format text: JAPANESE INTERMEDIATE CODE: R157
2024-05-09	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2025-10-30	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250

Publication	Publication Date	Title
JP6883988B2 (ja)	2021-06-09	ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US12528819B2 (en)	2026-01-20	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US12024525B2 (en)	2024-07-02	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP2021528427A (ja)	2021-10-21	認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
CN115175911A (zh)	2022-10-11	用于治疗认知损害的苯二氮䓬衍生物、组合物和方法
US11505555B2 (en)	2022-11-22	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40077472A (en)	2023-03-10	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40016046B (en)	2024-02-02	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40016046A (en)	2020-09-04	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1254300B (en)	2025-07-18	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1254300A1 (en)	2019-07-19	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1230170A1 (en)	2017-12-01	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1230170B (en)	2022-09-30	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment